AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
GlobalData on MSN13d
JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year aheadCFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January.
News Medical on MSN7d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CMMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
The mega investment is in line with Astrazeneca’s global ambition to achieve 80 billion dollars in Total Revenue and to bring ...
AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...
AstraZeneca said it has created more than 1,200 jobs and invested more than $1.3-billion CAD in Canada since 2023. The ...
AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater ...
U.K. pharmaceutical company says Canadian presence will contribute to its goal of bringing 20 new medicines to market by 2030 ...
AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be ...
AstraZeneca plans C$820 million investment in Canada to advance growing global hub and clinical delivery: Mississauga, Ontario Saturday, January 25, 2025, 09:00 Hrs [IST] AstraZen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback